7:50 AM ET
Earnings Call
▶ Call
Jade Biosciences Earnings Call: Key Takeaways
Jade Biosciences is advancing its pipeline with Jade 301 for Dermatomyositis, leveraging preclinical data showing 2.5-fold higher affinity and 8-fold greater potency than competitor Dazookibart, with a cash runway extending into Q4 2028.